A Phase 2 interventional study of Tulisokibart and Companion Diagnostic (CDx) Testing in Ulcerative Colitis, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 88 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Colitis, Ulcerative by Merck & Co., Inc — 2 open to participants now, 3 under way, 2 of them phase 3. Colitis, Ulcerative · Merck & Co., Inc.
Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 9th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 13 studies in Colitis, Ulcerative by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Canada, Chile and 9 more countries
Ages 18–75
Merck Sharp & Dohme LLC · Sites in United States, Czechia, France and 4 more countries
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 100 across the 11 interventional studies, 1,120 across the 2 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
1 of the studies in Colitis, Ulcerative by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07463183Merck Sharp & Dohme LLCA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are CDx+ and CDx- will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0, and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Drug: Tulisokibart
Participants who are CDx+ and CDx- will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Other: Placebo
Participants who are CDx+ will receive tulisokibart administered by intravenous (IV) infusion at 1000 mg on Day 1, Week 0 and 500 mg on the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Drug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing
Participants who are CDx+ will receive placebo administered by intravenous (IV) infusion on Day 1, Week 0 and the first day of Weeks 2, 6, and 10. After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.
Device: Companion Diagnostic (CDx) Testing · Other: Placebo
Administered by IV infusion
Also known as: MK-7240, PRA023
PRA023 CDx Genotyping Assay
Placebo administered by IV infusion
Percentage of Participants in Cohort 1 Achieving Clinical Remission
The 3-component Modified Mayo Score (MMS) ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding (RB), and stool frequency (SF) subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who experienced at least one AE is reported.
Time frame: Up to ~14 weeks
Percentage of Participants Who Discontinued Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who discontinued due to an AE is reported.
Time frame: Up to ~14 weeks
Percentage of Participants Who Had One or More Serious Adverse Events
Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Serious adverse events are defined as: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Life-threatening consequences; urgent intervention indicated, and death. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants experiencing a serious AE are presented.
Time frame: Up to ~14 weeks
Percentage of Participants in Cohort 1 With Endoscopic Improvement
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of the MMS of ≤ 1 with no friability. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 Achieving Clinical Response
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined as a reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 With Symptomatic Remission
RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 With Histologic Improvement
Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement
Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of MMS of ≤ 1 with no friability. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined by reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission
RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement
Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement
Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing
Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing
Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response
IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Percentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response
IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
Time frame: Baseline and Week 12
Participants with moderately to severely active ulcerative colitis were enrolled.
| Milestone | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Week 12 Responders: OLE 100 mg Tulisokibart | Week 12 Responders: OLE 250 mg Tulisokibart | Week 26 Responders: OLE 100 mg Tulisokibart | Week 26 Responders: OLE 250 mg Tulisokibart | Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 68 | 67 | 22 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 68 | 67 | 22 | 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received open-label induction regimen | 21 | 41 | 8 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 68 | 62 | 22 | 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Week 12 Responders: OLE 100 mg Tulisokibart | Week 12 Responders: OLE 250 mg Tulisokibart | Week 26 Responders: OLE 100 mg Tulisokibart | Week 26 Responders: OLE 250 mg Tulisokibart | Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 41 | 46 | 31 | 27 | 0 | 0 |
| Treated | 0 | 0 | 0 | 0 | 41 | 46 | 31 | 27 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 9 | 15 | 13 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 32 | 31 | 18 | 21 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 7 | 7 | 10 | 9 | 0 | 0 |
| Withdrew: Transitioned to a separate extension study | 0 | 0 | 0 | 0 | 23 | 24 | 7 | 11 | 0 | 0 |
| Milestone | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Week 12 Responders: OLE 100 mg Tulisokibart | Week 12 Responders: OLE 250 mg Tulisokibart | Week 26 Responders: OLE 100 mg Tulisokibart | Week 26 Responders: OLE 250 mg Tulisokibart | Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 13 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 13 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Withdrew: Transitioned to a separate extension study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 6 |
The 3-component Modified Mayo Score (MMS) ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding (RB), and stool frequency (SF) subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 Achieving Clinical Remission | 26.5 | 1.5 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who experienced at least one AE is reported.
| Percentage of participants | All Cohorts (Cohort 1 & Cohort 2) Tulisokibart | All Cohorts (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 45.6 | 43.2 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants who discontinued due to an AE is reported.
| Percentage of participants | All Cohorts (Cohort 1 & Cohort 2) Tulisokibart | All Cohorts (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Discontinued Due to an AE | 1.1 | 3.4 |
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of the MMS of ≤ 1 with no friability. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With Endoscopic Improvement | 36.8 | 6.0 |
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined as a reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 Achieving Clinical Response | 66.2 | 22.4 |
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical remission is defined as endoscopic subscore of 0 or 1, RB subscore of 0, and SF subscore of 0 or 1 and not greater than baseline. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Remission | 31.6 | 10.8 |
RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With Symptomatic Remission | 19.1 | 6.0 |
Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With Histologic Improvement | 46.2 | 17.5 |
Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Improvement | 30.8 | 3.5 |
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Endoscopic improvement is defined by endoscopy subscore of MMS of ≤ 1 with no friability. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Endoscopic Improvement | 36.8 | 18.9 |
The 3-component MMS ranges from 0 to 9 and is composed of endoscopic assessment, RB, and SF subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease. Clinical response is defined by reduction from Baseline ≥ 2 points and ≥ 30% in 3-component Modified Mayo Score, accompanied by a reduction ≥ 1 in RB subscore or absolute RB subscore ≤ 1. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
| Percentage of Participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Clinical Response | 55.3 | 32.4 |
RB, and SF subscores each range from 0 to 3, with higher scores indicating more severe disease. Symptomatic remission is defined as participants with SF subscore = 0 and RB subscore = 0. The percentage of participants who achieved symptomatic remission is presented. Per protocol participants who were CDx+ (Cohort 1 + Cohort 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Symptomatic Remission | 21.1 | 10.8 |
Histologic improvement is defined as Geboes score ≤ 3.1. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. A higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic Improvement | 55.6 | 26.7 |
Histologic-endoscopic mucosal improvement is defined as a Geboes score ≤ 3.1 and endoscopy subscore of the MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Improvement | 38.9 | 16.7 |
Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With Histologic-endoscopic Mucosal Healing | 30.8 | 3.5 |
Histologic-endoscopic mucosal improvement is defined as Geboes score ≤ 2B.1 and endoscopy subscore of MMS ≤ 1 with no friability. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. The endoscopic subscore of the MMS ranges from 0-3. For both scales a higher score indicates more severe disease. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Were CDx+ (Cohorts 1 + 2) With Histologic-endoscopic Mucosal Healing | 38.9 | 16.7 |
IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants in Cohort 1 were analyzed for this outcome measure.
| Percentage of participants | Cohort 1 Tulisokibart | Cohort 1 Placebo |
|---|---|---|
| Percentage of Participants in Cohort 1 With an Inflammatory Bowel Disease Questionnaire (IBDQ) Response | 82.4 | 49.3 |
IBDQ is a self-administered, disease-specific Health-Related Quality of Life (HRQOL) instrument for subjects with IBD. The IBDQ covers 4 dimensions and 32 questions: bowel symptoms, systemic symptoms, emotional function, and social function. Items are scored on a 7-point Likert scale (1 = all of the time and 7 = none of the time), for a total global score in the range 32 to 224 (with higher scores indicating better HRQOL). IBDQ response, as defined by ≥ 16-point increase from Baseline at Week 12. Per protocol participants who were CDx+ (Cohorts 1 + 2) were analyzed for this outcome measure.
| Percentage of participants | CDx+ (Cohort 1 & Cohort 2) Tulisokibart | CDx+ (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Are CDx+ (Cohorts 1 + 2) Who Had an IBDQ Response | 76.3 | 56.8 |
Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0. Serious adverse events are defined as: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Life-threatening consequences; urgent intervention indicated, and death. Per protocol, adverse events are reported by treatment with tulisokibart or placebo regardless of assigned cohort. Participants received identical treatment regiments regardless of cohort. The percentage of participants experiencing a serious AE are presented.
| Percentage of participants | All Cohorts (Cohort 1 & Cohort 2) Tulisokibart | All Cohorts (Cohort 1 & Cohort 2) Placebo |
|---|---|---|
| Percentage of Participants Who Had One or More Serious Adverse Events | 1.1 | 8.0 |
Collected over Up to approximately 43 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Tulisokibart | 0/68 (0%) | 0/68 (0%) | 14/68 (20.6%) |
| Cohort 1 Placebo | 0/67 (0%) | 6/67 (9%) | 10/67 (14.9%) |
| Cohort 2 Tulisokibart | 0/22 (0%) | 1/22 (4.5%) | 2/22 (9.1%) |
| Cohort 2 Placebo | 0/21 (0%) | 1/21 (4.8%) | 6/21 (28.6%) |
| Open-label Induction | 0/82 (0%) | 0/82 (0%) | 12/82 (14.6%) |
| Week 12 Responders: OLE 100 mg Tulisokibart | 0/41 (0%) | 3/41 (7.3%) | 23/41 (56.1%) |
| Week 12 Responders: OLE 250 mg Tulisokibart | 0/46 (0%) | 2/46 (4.3%) | 28/46 (60.9%) |
| Week 26 Responders: OLE 100 mg Tulisokibart | 0/31 (0%) | 0/31 (0%) | 16/31 (51.6%) |
| Week 26 Responders: OLE 250 mg Tulisokibart | 0/27 (0%) | 3/27 (11.1%) | 15/27 (55.6%) |
| Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | 0/24 (0%) | 1/24 (4.2%) | 11/24 (45.8%) |
| Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Open-label Induction | Week 12 Responders: OLE 100 mg Tulisokibart | Week 12 Responders: OLE 250 mg Tulisokibart | Week 26 Responders: OLE 100 mg Tulisokibart | Week 26 Responders: OLE 250 mg Tulisokibart | Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/68 | 5/67 | 0/22 | 0/21 | 0/82 | 1/41 | 1/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Post procedural cellulitisInfections and infestations | 0/68 | 0/67 | 0/22 | 1/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/68 | 0/67 | 1/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Umbilical herniaGastrointestinal disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 1/24 | 0/13 |
| Intestinal stenosisGastrointestinal disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 1/27 | 0/24 | 0/13 |
| Large intestine perforationGastrointestinal disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 1/27 | 0/24 | 0/13 |
| Clostridium difficile infectionInfections and infestations | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 1/27 | 0/24 | 0/13 |
| ConcussionInjury, poisoning and procedural complications | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 1/41 | 0/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 1/41 | 0/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Radius fractureInjury, poisoning and procedural complications | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 1/41 | 0/46 | 0/31 | 0/27 | 0/24 | 0/13 |
| Event | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Open-label Induction | Week 12 Responders: OLE 100 mg Tulisokibart | Week 12 Responders: OLE 250 mg Tulisokibart | Week 26 Responders: OLE 100 mg Tulisokibart | Week 26 Responders: OLE 250 mg Tulisokibart | Week 12 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg | Week 26 Responders: OLE 100 mg Tulisokibart Escalated to 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/68 | 1/67 | 0/22 | 3/21 | 3/82 | 11/41 | 17/46 | 12/31 | 13/27 | 2/24 | 2/13 |
| Upper respiratory tract infectionInfections and infestations | 1/68 | 3/67 | 1/22 | 1/21 | 2/82 | 7/41 | 6/46 | 2/31 | 2/27 | 5/24 | 1/13 |
| NasopharyngitisInfections and infestations | 1/68 | 2/67 | 1/22 | 1/21 | 3/82 | 3/41 | 5/46 | 1/31 | 1/27 | 3/24 | 1/13 |
| HeadacheNervous system disorders | 3/68 | 3/67 | 0/22 | 0/21 | 2/82 | 1/41 | 1/46 | 0/31 | 1/27 | 3/24 | 0/13 |
| COVID-19Infections and infestations | 5/68 | 3/67 | 0/22 | 1/21 | 2/82 | 4/41 | 2/46 | 0/31 | 2/27 | 2/24 | 0/13 |
| Back painMusculoskeletal and connective tissue disorders | 2/68 | 0/67 | 0/22 | 0/21 | 0/82 | 1/41 | 1/46 | 3/31 | 0/27 | 1/24 | 0/13 |
| TinnitusEar and labyrinth disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 1/27 | 2/24 | 0/13 |
| Atrial fibrillationCardiac disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 0/24 | 1/13 |
| Anal pruritusGastrointestinal disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 0/24 | 1/13 |
| Umbilical herniaGastrointestinal disorders | 0/68 | 0/67 | 0/22 | 0/21 | 0/82 | 0/41 | 0/46 | 0/31 | 0/27 | 0/24 | 1/13 |
| Age, Continuous(Years) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.4 ± 14.4 | 42.2 ± 16.3 | 38.1 ± 18.2 | 38.5 ± 11.4 | 40.6 ± 15.3 |
| Sex: Female, Male(Participants) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Female | 34 | 29 | 10 | 4 | 77 |
| Male | 34 | 38 | 12 | 17 | 101 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 1 | 1 | 8 |
| Not Hispanic or Latino | 60 | 62 | 19 | 19 | 160 |
| Unknown or Not Reported | 4 | 3 | 2 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 2 |
| White | 65 | 57 | 17 | 20 | 159 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 2 | 6 | 3 | 1 | 12 |
| CDx+/CDx-(Participants) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| CDx+ | 16 | 16 | 22 | 21 | 75 |
| CDx- | 52 | 51 | 0 | 0 | 103 |
| Body Mass Index (BMI)(Weight (kg) / [Height (m)]^2) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Mean | 25.71 ± 7.029 | 25.52 ± 5.033 | 25.11 ± 4.539 | 26.37 ± 5.518 | 25.63 ± 5.845 |
| Height(Centimeters (cm)) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Mean | 169.91 ± 9.798 | 172.61 ± 9.185 | 172.31 ± 8.729 | 173.26 ± 8.418 | 171.61 ± 9.317 |
| Weight(Kilograms (kg)) | Cohort 1 Tulisokibart | Cohort 1 Placebo | Cohort 2 Tulisokibart | Cohort 2 Placebo | Total |
|---|---|---|---|---|---|
| Mean | 73.89 ± 19.653 | 76.59 ± 18.482 | 74.62 ± 14.985 | 79.36 ± 14.984 | 75.64 ± 18.135 |
10 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2021 to primary completion in Jun 2023, 22 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 22 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tulisokibart
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →